Literature DB >> 12650761

Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry.

Valerie A Frerichs1, Robin DiFrancesco, Gene D Morse.   

Abstract

A method for the analysis of six protease inhibitors and one metabolite has been developed and validated. Amprenavir, ritonavir, saquinavir, lopinavir, indinavir, nelfinavir, and an active metabolite of nelfinavir (M8) are quantitated using reversed-phase liquid chromatography coupled to tandem mass spectrometry, equipped with an electrospray ionization source (ESI-LC-MS-MS). The validation data presented here shows that the method allows the rugged analysis of these species from one aliquot. The evolution of complex drug interactions assessments and the clinical use of therapeutic drug monitoring for these antiretrovirals will be a potential immediate application of this method.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12650761     DOI: 10.1016/s1570-0232(02)01002-4

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  8 in total

1.  Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.

Authors:  Diane T Holland; Robin DiFrancesco; Judith Stone; Fayez Hamzeh; James D Connor; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.

Authors:  Patrick F Smith; Gregory K Robbins; Robert W Shafer; Hulin Wu; Song Yu; Martin S Hirsch; Thomas C Merigan; Jeong-Gun Park; Alan Forrest; Margaret A Fischl; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver.

Authors:  Andrew J Ocque; Colleen E Hagler; Robin Difrancesco; Yvonne Woolwine-Cunningham; Cindy J Bednasz; Gene D Morse; Andrew H Talal
Journal:  Bioanalysis       Date:  2016-06-09       Impact factor: 2.681

4.  Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.

Authors:  Gene D Morse; Susan Rosenkranz; Michael F Para; Yoninah Segal; Robin Difrancesco; Elizabeth Adams; Barbara Brizz; Kevin E Yarasheski; Richard C Reichman
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks.

Authors:  Olanrewaju Okusanya; Alan Forrest; Robin DiFrancesco; Sanela Bilic; Susan Rosenkranz; Michael F Para; Elizabeth Adams; Kevin E Yarasheski; Richard C Reichman; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

6.  Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.

Authors:  Robert DiCenzo; Derick R Peterson; Kim Cruttenden; Peter Mariuz; Naser L Rezk; Jill Hochreiter; Harris Gelbard; Giovanni Schifitto
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

7.  Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.

Authors:  Qing Ma; Alan Forrest; Susan L Rosenkranz; Michael F Para; Kevin E Yarasheski; Richard C Reichman; Gene D Morse
Journal:  Biopharm Drug Dispos       Date:  2008-03       Impact factor: 1.627

8.  Protease inhibitor levels in hair strongly predict virologic response to treatment.

Authors:  Monica Gandhi; Niloufar Ameli; Peter Bacchetti; Stephen J Gange; Kathryn Anastos; Alexandra Levine; Charles L Hyman; Mardge Cohen; Mary Young; Yong Huang; Ruth M Greenblatt
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.